Bronx Prevention Center

ICAP’s two research centers in New York, the Bronx Prevention Center and the Harlem Prevention Center, are hubs of research in New York City that have been historically underserved and disproportionately impacted by the HIV epidemic and, more recently, the COVID-19 epidemic. ICAP works with local community-based organizations, religious leaders, and advocates to promote community awareness of, and engagement with the research studies.

The Community Advisory Board (CAB) for the ICAP Clinical Trials Unit (CTU) provides guidance and feedback on proposed studies, outreach strategies, feedback on study materials, and information regarding community perceptions of the potential or current research studies.

Current studies include investigations of antibody-mediated prevention using broadly neutralizing antibodies (bnAbs) to prevent HIV or COVID-19, an injectable long-acting pre-exposure prophylaxis (PrEP) option, mobile technologies to improve PrEP adherence, integrated care for people who inject opiates, HIV vaccine studies, and studies of COVID-19 immunity, vaccine efficacy, and treatment among others.


HPTN 094: The INTEGRA Study

  • current
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care Web Links: https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190 ...

HTPN 083: Give PrEP a Shot

  • current
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.Closed to enrollment, in active study follow-up Web Links: https://clinicaltrials.gov/ct2/show/NCT02720094  https://www.hptn.org/research/studies/hptn083  ...

Making PrEP Smart

  • current
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking ...

ICAP in Bronx

Active Years

2010 to present

Key Technical Areas
  • COVID-19 

  • HIV 

  • Sexually transmitted infections 

  • Addiction  

  • Health disparities 

  • Stigma and Discrimination 

Current Funders
  • National Institute of Health
    • National Institute of Allergy and Infectious Diseases (NIH/NIAID)
      Department of Health and Human Services (DHHS)
    • Family Health International (FHI)
    • Fred Hutchinson Cancer Research Center
  • AstraZeneca
  • Merck
  • Gilead



Site Leader

Ellen Morrison, MD, MPH

Dr. Ellen Morrison is the Site Leader of the Columbia University Mailman School of Public Health ICAP Bronx Prevention Center CRS. She is a practicing board-certified Infectious Disease physician who has been on the full-time faculty at the Columbia University Irving Medical Center for more than 30 years.  Dr. Morrison has focused on clinical education, HIV testing and care, quality improvement, maternal infections, treatment of sexually transmitted infections, and the ethical review and conduct of clinical research.  She joined ICAP in 2018, where she serves as a Senior Technical Specialist Advisor for ICAP’s global health initiatives and is an investigator and site lead at the Bronx Prevention Center.  Dr. Morrison continues work on HIV prevention, including investigation of the provision of integrated services on a mobile van to engage out-of-care injection opiate users and work on COVID-19 vaccines, testing of monoclonal antibodies, and other COVID-19 treatment modalities.

Jobs in the United States

See the ICAP careers page to search all job listings.